



ANDA 210111

**ANDA APPROVAL**

Breckenridge Pharmaceutical, Inc.  
15 Massirio Drive, Suite 201  
Berlin, CT 06037  
Attention: Theresa King  
Senior Director Regulatory Affairs

Dear Madam:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on February 8, 2017, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Pomalidomide Capsules, 1 mg, 2 mg, 3 mg, and 4 mg.

Reference is also made to the complete response letter issued by this office on August 26, 2019, and to any amendments thereafter.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval under the FD&C Act. Accordingly, the ANDA is **approved**, effective on the date of this letter. We have determined your Pomalidomide Capsules, 1 mg, 2 mg, 3 mg, and 4 mg, to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Pomalyst Capsules, 1 mg, 2 mg, 3 mg, and 4 mg, of Celgene Corporation (Celgene).

The RLD upon which you have based your ANDA, Celgene’s Pomalyst Capsules, 1 mg, 2 mg, 3 mg, and 4 mg, is subject to periods of patent protection. The following patents and expiration dates (with pediatric exclusivity added) are currently listed in the Agency’s publication titled *Approved Drug Products with Therapeutic Equivalence Evaluations* (the “Orange Book”):

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
8,198,262 (the '262 patent)	December 17, 2025
8,673,939 (the '939 patent)	November 15, 2023
8,735,428 (the '428 patent)	November 15, 2023
8,828,427 (the '427 patent)	December 21, 2031

9,993,467 (the '467 patent)      November 19, 2030

10,555,939 (the '939 patent)      November 19, 2030

Your ANDA contains paragraph IV certifications to each of the patents<sup>1</sup> under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Pomalidomide Capsules, 1 mg, 2 mg, 3 mg, and 4 mg, under this ANDA. You have notified the Agency that Breckenridge Pharmaceutical, Inc. (Breckenridge) complied with the requirements of section 505(j)(2)(B) of the FD&C Act. Litigation was initiated within the statutory 45-day period against Breckenridge for infringement of the '262, '939, '428, and '427 patents in the United States District Court for the District of New Jersey [Celgene Corporation v. Breckenridge Pharmaceutical, Inc. et al., Civil Action No. 17-03387 (consolidated)]. Although this litigation remains ongoing, the 7.5-year period provided for in sections 505(j)(5)(B)(iii) and 505(j)(5)(F)(ii) of the FD&C Act, during which FDA was precluded from approving your ANDA, has expired.

With respect to 180-day generic drug exclusivity, we note that Breckenridge was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Pomalidomide Capsules, 1 mg, 2 mg, 3 mg, and 4 mg. Therefore, with this approval, Breckenridge may be eligible for 180 days of shared generic drug exclusivity for Pomalidomide Capsules, 1 mg, 2 mg, 3 mg, and 4 mg. This exclusivity, which is provided for under 505(j)(5)(B)(iv) of the FD&C Act, would begin to run from the date of the commercial marketing by any first applicant, as identified in section 505(j)(5)(B)(iv). The Agency notes that Breckenridge failed to obtain tentative approval of this ANDA within 30 months after the date of which the ANDA was filed. See section 505(j)(5)(D)(i)(IV) of the FD&C Act (forfeiture of exclusivity for failure to obtain tentative approval). The Agency is not, however, making a formal determination at this time of Breckenridge's eligibility for 180-day generic drug exclusivity. It will do so only if a subsequent paragraph IV applicant becomes eligible for full approval (a) within 180 days after Breckenridge or any first applicant begins commercial marketing of Pomalidomide Capsules, 1 mg, 2 mg, 3 mg, and 4 mg, or (b) at any time prior to the expiration of the '262, '939, '428, and '427 patents if Breckenridge or any first applicant has not begun commercial marketing. Please submit correspondence to this ANDA notifying the Agency within 30 days of the date of the first commercial marketing of this drug product or the RLD. If you do not notify the Agency within 30 days, the date of first commercial marketing will be deemed to be the date of the drug product's approval. See 21 CFR 314.107(c)(2).

Under section 506A of the FD&C Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

## **RISK EVALUATION AND MITIGATION STRATEGY (REMS) REQUIREMENTS**

Section 505-1 of the FD&C Act authorizes FDA to require the submission of a risk evaluation and mitigation strategy (REMS), if FDA determines that such a strategy is necessary to ensure that the benefits of the drug outweigh the risks [section 505-1(a)].

In accordance with section 505-1(i) of the FD&C Act, a drug that is the subject of an ANDA under section 505(j) is subject to certain elements of the REMS required for the applicable listed drug.

The details of the REMS requirements were outlined in our REMS notification letter dated March 28, 2017.

Your final proposed REMS, received on July 17, 2020; is approved, and will be posted on the FDA REMS website: <http://www.fda.gov/remis>

The REMS consists of ETASU and an implementation system.

Your REMS must be fully operational before you introduce Pomalidomide into interstate commerce.

Your REMS, known as the Pomalidomide REMS Program, is approved as a separate REMS program from that of the reference listed drug, using a different, comparable aspect of the elements to assure safe use. Pursuant to section 505-1(i)(3), FDA is requiring that this REMS Program can be used with respect to any other drug that is the subject of an application under section 355(j) or 355(b) of the FD&C Act that references the same listed drug.

Under section 505-1(g)(2)(C) of the FD&C Act, FDA can require the submission of a REMS assessment if FDA determines an assessment is needed to evaluate whether the REMS should be modified to ensure the benefits of the drug outweigh the risks or to minimize the burden on the healthcare delivery system of complying with the REMS. FDA has determined that assessments are needed for the Pomalidomide REMS Program.

Additionally, the details for what should be included in your REMS assessments and the dates of the REMS assessments are listed in Appendix 1.

If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively, updates may be made by modifying the complete previous REMS supporting document,

with all changes marked and highlighted. Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:

**ANDA 210111 REMS CORRESPONDENCE**

(insert concise description of content in bold capital letters, e.g.,

**UPDATE TO REMS SUPPORTING DOCUMENT - ASSESSMENT  
METHODOLOGY**

We remind you that you must include an adequate rationale to support a proposed REMS modification for the addition, modification, or removal of any goal or element of the REMS, as described in section 505-1(g)(4) of the FD&C Act.

We also remind you that section 505-1(f)(8) of the FD&C Act prohibits holders of an approved covered application from using any element to assure safe use to block or delay approval of an application under section 505(b)(2) or (j). A violation of this provision in 505-1(f) could result in enforcement action.

Prominently identify any submission containing a REMS assessment or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

**ANDA 210111 REMS ASSESSMENT**

*or*

**NEW SUPPLEMENT FOR ANDA 210111/S-000  
CHANGES BEING EFFECTED IN 30 DAYS  
PROPOSED MINOR REMS MODIFICATION**

*or*

**NEW SUPPLEMENT FOR ANDA 210111/S-000  
PRIOR APPROVAL SUPPLEMENT  
PROPOSED MAJOR REMS MODIFICATION**

*or*

**NEW SUPPLEMENT FOR ANDA 210111/S-000  
PRIOR APPROVAL SUPPLEMENT  
PROPOSED REMS MODIFICATIONS DUE TO SAFETY LABELING  
CHANGES SUBMITTED IN SUPPLEMENT XXX**

Should you choose to submit a REMS revision, prominently identify the submission containing the REMS revisions with the following wording in bold capital letters at the top of the first page of the submission:

**REMS REVISION FOR ANDA 210111**

To facilitate review of your submission, we request that you submit your proposed modified REMS and other REMS-related materials in Microsoft Word format. If certain documents, such as enrollment forms, are only in PDF format, they may be submitted as such, but the preference is to include as many as possible in Word format.

**SUBMISSION OF REMS DOCUMENT IN SPL FORMAT**

In addition to submitting the proposed REMS as described above, you can also submit the REMS document in Structured Product Labeling (SPL) format. If you intend to submit the REMS document in SPL format, include the SPL file with your proposed REMS submission.

For more information on submitting REMS in SPL format, please email [REMSWebsite@fda.hhs.gov](mailto:REMSWebsite@fda.hhs.gov).

**REPORTING REQUIREMENTS**

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98 and at section 506I of the FD&C Act. The Agency should be advised of any change in the marketing status of this drug or if this drug will not be available for sale after approval. In particular, under section 506I(b) of the FD&C Act, you are required to notify the Agency in writing within 180 days from the date of this letter if this drug will not be available for sale within 180 days from the date of approval. As part of such written notification, you must include (1) the identity of the drug by established name and proprietary name (if any); (2) the ANDA number; (3) the strength of the drug; (4) the date on which the drug will be available for sale, if known; and (5) the reason for not marketing the drug after approval.

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling materials prior to publication or dissemination. Please note that these submissions are voluntary. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert (PI), Medication Guide, and patient PI (as applicable) to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

You must also submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>. Information and Instructions for completing the form can be found at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

### **ANNUAL FACILITY FEES**

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions<sup>2</sup> with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1st of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the Federal Register notice announcing facility fee amounts.

All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling

[21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <https://www.fda.gov/media/71211/download>. The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

*{See appended electronic signature page}*

For Edward M. Sherwood  
Director  
Office of Regulatory Operations  
Office of Generic Drugs  
Center for Drug Evaluation and Research

---

<sup>1</sup> The Agency notes that the '467 and '939 patents were submitted to the Agency after submission of your ANDA. Litigation, if any, with respect to these patents would not create a statutory stay of approval.

<sup>2</sup> Some of these provisions were amended by the Generic Drug User Fee Amendments of 2017 (GDUFA II) (Public Law 115-52, Title III).

ENCLOSURE:

REMS

## Appendix I: REMS Assessment Plan

Pomalidomide REMS Sponsors will submit Pomalidomide REMS assessments to the FDA annually from the date of initial approval of the Pomalidomide REMS. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that REMS assessment. The Pomalidomide REMS Sponsors will submit each REMS assessment so that it will be received by the FDA on or before the due date.

For each annual Pomalidomide REMS assessment report, the following information will be provided. A tabular format will be utilized when appropriate.

The Pomalidomide Shared System REMS Assessment Plan will include, but is not limited to, the following information:

### Program Implementation and Operations

1. REMS Program Implementation (1-year assessment only)
  - a. Date of first commercial distribution of generic pomalidomide
  - b. Date when the Pomalidomide REMS website became live and fully operational
  - c. Date when healthcare providers could become certified
  - d. Date when pharmacies could become certified
  - e. Date when patients could become enrolled
  - f. Date when the REMS Coordinating Center was established and fully operational
2. REMS Certification and Enrollment Statistics (per current and previous two reporting periods and cumulatively)
  - a. Certification of healthcare providers (HCPs)
    - I. Number of new certifications of HCPs, indicating whether previously certified or not, stratified by professional designation (i.e. MD, DO, PA, NP), and geographic region (defined by US Census).
    - II. Number of active HCPs (have prescribed pomalidomide at least once during the reporting period) stratified by professional designation (i.e. MD, DO, PA, NP), and geographic region (defined by US Census).
  - b. Certification of pharmacies
    - I. Number of new certified pharmacies stratified by geographic region (defined by US Census).
    - II. Number of active certified pharmacies (have filled or ordered at least one prescription for pomalidomide during the reporting period) stratified by geographic region (defined by US Census).
  - c. Patient enrollment
    - I. Number of new patients enrolled stratified by age, gender, diagnosis, and patient reproductive status ( i.e. females of reproductive potential (FRP) and females of non-reproductive potential (FNRP)).

- II. Number of active patients (have received at least one shipment of pomalidomide during the reporting period) stratified by age gender, diagnosis, and patient reproductive status (i.e. females of reproductive potential (FRP) and females of non-reproductive potential (FNRP)).
3. Utilization Data (per current and previous two reporting periods and cumulatively)
  - a. Number and percentage of unique patients who received pomalidomide, new and total, stratified by patient type grouped by the following age ranges:
    - I. < 6
    - II. 6 - < 18
    - III. 18 - 49
    - IV. 50+
  - b. Number and percentage of prescriptions (new and refills) dispensed for FRPs and FNRP stratified by:
    - I. Healthcare provider specialty
    - II. Reproductive Status (FRP or FNRP)
    - III. Patient age as outlined in 3.a above
4. Compliance with the Pomalidomide REMS (per current and previous two reporting periods and cumulatively; where applicable)
  - a. Provide a report of audit activities for stakeholders (pharmacies, distributors, and the REMS Coordinating Center)
  - b. Provide a copy of the non-compliance plan to include the following:
    - I. Criteria for non-compliance
    - II. Actions taken to address non-compliance for each event identified
    - III. Criteria for de-certification
  - c. Provide a copy of the audit plan.
  - d. Report of audit findings.
    - I. The number of audits expected, and the number of audits conducted
    - II. The number and type of deficiencies noted
      - 1) Number that successfully completed a corrective and preventative action (CAPA) plan within 30 days of receipt of CAPA
      - 2) Describe actions taken for any that did not complete the CAPA within 30 days of receipt of CAPA
      - 3) Include a unique ID for each stakeholder that had deviations to track deviations over time
    - III. Documentation of completion of training for relevant staff
    - IV. The existence of documented processes and procedure for complying with the REMS
    - V. A comparison of the findings to findings of previous audits and assess whether any trends are noted
  - e. Non-compliance events: for each event provide the following:
    - I. Source of the report
    - II. Description of the event

- III. Cause of the event
- IV. Corrective actions taken
- V. Event:
  - 1) Number of pomalidomide prescriptions dispensed that were written by non-certified prescribers
  - 2) Number of pomalidomide prescriptions dispensed by non-certified pharmacies
  - 3) Number of pomalidomide prescriptions dispensed to de-enrolled or non-enrolled patients
  - 4) Number of times a pomalidomide prescription was dispensed without obtaining a confirmation number
  - 5) Number of prescriptions dispensed of greater than a 28 days' supply
  - 6) Number of shipments sent to non-certified pharmacies, sources of the reports, and actions taken to prevent future occurrences
  - 7) Number of prescribers and pharmacies who were de-certified (suspended or deactivated) for non-compliance and reasons for de-certification

5. REMS Infrastructure and Performance (per current and previous two reporting periods and cumulatively; where applicable)

a. REMS Coordinating Center

- I. Number of contacts by stakeholder type (patients, healthcare providers, pharmacies, wholesaler(s)/distributor(s), other)
- II. Summary of reasons for calls (e.g., enrollment question, location of a pharmacy) and by reporter (authorized representative, pharmacy, healthcare provider, patient, other)
- III. Summary of frequently asked questions (FAQ) by stakeholder type
- IV. Summary report of REMS-related problems identified and resulting corrective actions

b. REMS Website

- I. Number of visits and unique visits to the REMS website
- II. Number of REMS materials downloaded or printed for each material

**Health Outcomes and/or Surrogates of Health Outcomes**

6. Pregnancy Metrics (per reporting period and cumulatively)

- a. Number of pregnancies reported stratified by the source of the report (spontaneous report, reported via the REMS program, etc.)
- b. Pregnancy rate
- c. A summary of both US and worldwide pregnancy cases, including but not limited to the following information:
  - I. Event identification number
  - II. Age of the patient
  - III. Contraceptive methods used
  - IV. Outcome of each pregnancy

- V. Weeks gestation at termination if pregnancy is terminated
- d. Follow-up of outstanding pregnancy reports
- e. Root cause analysis of each reported pregnancy
- f. Link to most recent Periodic Safety Update Report (PSUR) or Periodic Benefit-Risk Evaluation Report (PBRER) that provides information on worldwide pregnancies. Discussion of any new information provided in the PSUR or PBRER regarding pregnancy.

### Safe-Use Behaviors

- 7. Change in Reproductive Status as reported via the required prescriber survey (per current and previous two reporting periods and cumulatively)
  - a. Number of status changes to a female of reproductive potential, including:
    - i. Number of times pomalidomide was dispensed prior to the patient getting her first pregnancy test following the status change, any resulting adverse events, and corrective actions
  - b. Number of status changes to a female of non-reproductive potential, including rationale for the change as indicated on the survey.
    - i. Number of female patients for whom pregnancy testing can be discontinued because the patient has had a natural menopause for at least 24 consecutive months, a hysterectomy, and/or bilateral oophorectomy

- 8. Documentation of safe-use conditions (per current and previous two reporting periods and cumulatively, where applicable)  
Based on information collected from the mandatory surveys (used to document safe-use conditions) provide information that could represent potential fetal exposure or that might result in a delay or interruption in treatment.  
Provide the following in a tabular format:
  - a. The total number of authorization numbers issued and the total number of authorization numbers flagged
  - b. The number and proportion of failed authorizations intended for an FRP due to responses in the mandatory surveys related to pregnancy testing that did not meet the REMS requirements
  - c. The number and proportion of failed authorizations that caused a delay in treatment initiation or a gap in therapy for patients due to REMS processes related to the mandatory surveys compared to the total authorization numbers. Include the time to resolution of failed authorizations in days (mean, minimum, maximum) for the reporting period and for each previous reporting period. Include the number of patients with a delay in treatment or a gap in therapy due to REMS processes related to the mandatory surveys.

### Knowledge

- 9. Inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions for pomalidomide (per current and previous two reporting periods and cumulatively, where applicable)

- a. Ensure that pomalidomide will only be dispensed to patients enrolled in the pomalidomide REMS program with evidence or other documentation of safe-use conditions
    - I. Number of patient surveys that met the REMS requirements relating to knowledge compared to the total number of patient surveys submitted per patient risk category
    - II. Number of patient surveys that did not meet the REMS requirements related to knowledge as compared to the total number of patient surveys submitted per patient risk category. Include the time to resolution in days (mean, minimum, maximum) for the reporting period and for each previous reporting period. Include outreach strategies taken by the REMS Coordinating Center to resolve unacceptable safe-use survey responses.
  - b. Ensure healthcare providers counsel patients on the benefits and risks of pomalidomide therapy, including risks described in the boxed warnings
    - I. Number of prescriber surveys that met the REMS requirements reported per risk category
    - II. Number of prescriber surveys that did not meet the REMS requirements reported per risk category. Include the time to resolution in days (mean, minimum, maximum) for the reporting period and for each previous reporting period. Include outreach strategies taken by the REMS Coordinating Center to resolve unacceptable safe-use survey responses.
  - c. Educate pharmacies on the risks and safe-use conditions of pomalidomide
    - I. Total number of pharmacy certification quizzes administered
    - II. Number of pharmacies with a passing rate/total number of certified pharmacies on the last day of the reporting period
10. Pomalidomide REMS Knowledge, Attitudes, and Behavior Survey (KAB)  
(beginning with the 1-year assessment report and annually thereafter with each assessment report)

The first KAB assessment of prescribers and patients will be completed for inclusion in the 1-year FDA Assessment Report, and will be repeated annually.

The KAB surveys will assess the following:

- a. Patient understanding of:
  - I. The serious risks associated with the use of pomalidomide
  - II. The importance of regular pregnancy testing as described in the **Patient Guide**
- b. Prescriber understanding of:
  - I. The serious risks associated with the use of pomalidomide
  - II. The requirements for monitoring reproductive status and pregnancy status described in the **Prescriber Guide**

- III. The need to counsel patients about the risks associated with the use of pomalidomide and the need for monitoring as described in the **Prescriber Guide**
  - c. Pharmacist understanding of:
    - I. The serious risks associated with the use of pomalidomide
    - II. The training and dispensing procedures for pomalidomide as described in the **Pharmacy Guide**
    - III. The need to counsel patients on the benefits and risks of pomalidomide using the **Education and Counseling Checklist for Pharmacies**
11. The requirements for assessments of an approved REMS under section 505-1(g)(3) include, with respect to each goal included in the strategy, an assessment of the extent to which the approved strategy, including each element of the strategy, is meeting the goal or whether one or more such goals or such elements should be modified.



Catherine  
Poole

Digitally signed by Catherine Poole

Date: 10/30/2020 12:23:17PM

GUID: 5407887a000a1c0c26055eafb8e3258a